Flexion Therapeutics Stock Price, News & Analysis (NASDAQ:FLXN)

$25.22 0.77 (3.15 %)
(As of 12/17/2017 12:24 PM ET)
Previous Close$25.22
Today's Range$24.26 - $25.67
52-Week Range$16.51 - $32.25
Volume3.59 million shs
Average Volume1.13 million shs
Market Capitalization$946.78 million
P/E RatioN/A
Dividend YieldN/A
Beta1.15

About Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics logoFlexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.

Receive FLXN News and Ratings via Email

Sign-up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FLXN
CUSIPN/A
Phone781-305-7777

Debt

Debt-to-Equity Ratio0.87%
Current Ratio12.93%
Quick Ratio12.93%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$6.01 per share
Price / Book4.20

Profitability

Trailing EPS($3.51)
Net Income$-71,890,000.00
Net MarginsN/A
Return on Equity-60.29%
Return on Assets-38.08%

Miscellaneous

Employees95
Outstanding Shares37,540,000

Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics Inc (NASDAQ:FLXN) posted its quarterly earnings results on Wednesday, August, 3rd. The specialty pharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.67) by $0.04. View Flexion Therapeutics' Earnings History.

Where is Flexion Therapeutics' stock going? Where will Flexion Therapeutics' stock price be in 2017?

9 Wall Street analysts have issued 12-month price objectives for Flexion Therapeutics' stock. Their forecasts range from $35.00 to $570.00. On average, they anticipate Flexion Therapeutics' stock price to reach $98.33 in the next twelve months. View Analyst Ratings for Flexion Therapeutics.

What are Wall Street analysts saying about Flexion Therapeutics stock?

Here are some recent quotes from research analysts about Flexion Therapeutics stock:

  • 1. According to Zacks Investment Research, "Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company's product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. " (11/1/2017)
  • 2. Cantor Fitzgerald analysts commented, "OpEx Increases in 2017: FLXN reported 4Q16 and YE results of ($0.79) and ($2.84), below our estimates due to higher R&D and SG&A expense. Management noted on the call that R&D expense should increase given the on going repeat-dose study and manufacturing ramp with SG&A ramping through the 2H17 as launch preparation get fully underway. FLXN finished the quarter with $210M in cash which we estimate gives them funding through mid-2018. We have adjusted our estimates to reflect quarter results. PDUFA and Beyond: We view the acceptance of the NDA without the need to provide additional data as an incremental positive, removing an overhang in the minds of some investors. We see investors now turning to the prospective label with the potential for differentiation in the diabetic sub-population and a repeat- dose sNDA filing which could be on label by 2019. Additional label expansion into other joints including shoulder and hip are also possibilities though not near term." (3/14/2017)
  • 3. BMO Capital Markets analysts commented, "While the company did not receive a priority review, we had not been expecting that, and had always assumed a standard 10-month review. It was good to see the FDA accept the NDA with no major issues, and we remain confident in the approval of Zilretta at the PDUFA. Reiterate our Outperform; FLXN remains a top pick." (2/7/2017)

Who are some of Flexion Therapeutics' key competitors?

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the folowing people:

  • Patrick J. Mahaffy, Chairman of the Board (Age 54)
  • Michael D. Clayman M.D., President, Chief Executive Officer, Co-Founder, Director (Age 65)
  • Neil Bodick M.D., Ph.D., Chief Scientific Officer (Age 70)
  • Mark Levine, Vice President, General Counsel (Age 43)
  • John Magee, Vice President - Sales
  • Mark Fraga, Vice President - Marketing
  • Dan Thornton, Vice President - Market Access
  • Scott Kelley M.D., Chief Medical Officer
  • Mark P. Stejbach, Director (Age 53)
  • Scott A. Canute, Independent Director (Age 57)

Who owns Flexion Therapeutics stock?

Flexion Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (10.79%), Bank of New York Mellon Corp (7.08%), Wasatch Advisors Inc. (2.68%), Pictet Asset Management Ltd. (1.89%), Peregrine Capital Management LLC (1.87%) and Schroder Investment Management Group (1.14%). Company insiders that own Flexion Therapeutics stock include C Ann Merrifield, Frederick W Driscoll, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Institutional Ownership Trends for Flexion Therapeutics.

Who sold Flexion Therapeutics stock? Who is selling Flexion Therapeutics stock?

Flexion Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Bank of New York Mellon Corp, Peregrine Capital Management LLC, Commonwealth of Pennsylvania Public School Empls Retrmt SYS, Schroder Investment Management Group, GSA Capital Partners LLP, Nicholas Investment Partners LP and Verde Servicos Internacionais S.A.. Company insiders that have sold Flexion Therapeutics company stock in the last year include Frederick W Driscoll and Neil Bodick. View Insider Buying and Selling for Flexion Therapeutics.

Who bought Flexion Therapeutics stock? Who is buying Flexion Therapeutics stock?

Flexion Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Gagnon Securities LLC, Pictet Asset Management Ltd., Uniplan Investment Counsel Inc., Russell Investments Group Ltd., Highbridge Capital Management LLC, Dupont Capital Management Corp, Virginia Retirement Systems ET AL and 1492 Capital Management LLC. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, Frederick W Driscoll, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Insider Buying and Selling for Flexion Therapeutics.

How do I buy Flexion Therapeutics stock?

Shares of Flexion Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Flexion Therapeutics' stock price today?

One share of Flexion Therapeutics stock can currently be purchased for approximately $25.22.

How big of a company is Flexion Therapeutics?

Flexion Therapeutics has a market capitalization of $946.78 million. The specialty pharmaceutical company earns $-71,890,000.00 in net income (profit) each year or ($3.51) on an earnings per share basis. Flexion Therapeutics employs 95 workers across the globe.

How can I contact Flexion Therapeutics?

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]


MarketBeat Community Rating for Flexion Therapeutics (FLXN)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  284 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  405
MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Flexion Therapeutics (NASDAQ:FLXN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.113.13
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $83.91$83.91$33.10$31.56
Price Target Upside: 249.77% upside249.77% upside37.24% upside85.20% upside

Flexion Therapeutics (NASDAQ:FLXN) Consensus Price Target History

Price Target History for Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics (NASDAQ:FLXN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017Northland SecuritiesReiterated RatingBuy$40.00N/AView Rating Details
10/30/2017Wells Fargo & CompanySet Price TargetBuy$39.00N/AView Rating Details
10/29/2017Royal Bank of CanadaSet Price TargetBuy$44.00N/AView Rating Details
10/10/2017LaidlawReiterated RatingBuy$35.00 -> $38.00N/AView Rating Details
10/10/2017Janney Montgomery ScottBoost Price TargetBuy -> Fair Value$570.00N/AView Rating Details
10/9/2017BMO Capital MarketsReiterated RatingOutperform$35.00 -> $37.00N/AView Rating Details
10/9/2017Needham & Company LLCBoost Price TargetBuy -> Buy$36.00 -> $42.00N/AView Rating Details
6/12/2017Cantor FitzgeraldSet Price TargetBuy$40.00LowView Rating Details
12/22/2016Raymond James FinancialInitiated CoverageStrong-Buy$35.00N/AView Rating Details
11/8/2016BCSLower Price Target$0.65 -> $0.02N/AView Rating Details
9/6/2016Lake Street CapitalReiterated RatingBuy$38.00N/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Flexion Therapeutics (NASDAQ:FLXN) Earnings History and Estimates Chart

Earnings by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics (NASDAQ FLXN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.80)($0.91)ViewListenView Earnings Details
5/4/2017Q1 2017($0.73)($0.75)ViewListenView Earnings Details
3/9/2017Q4 2016($0.71)($0.79)ViewListenView Earnings Details
11/7/2016Q3($0.63)($0.65)ViewListenView Earnings Details
8/3/2016Q2($0.67)($0.63)ViewN/AView Earnings Details
5/12/2016Q1($0.61)($0.78)ViewListenView Earnings Details
3/10/2016Q4 2015($0.58)($0.63)ViewN/AView Earnings Details
11/9/2015Q3($0.60)($0.52)ViewListenView Earnings Details
8/6/2015Q215($0.54)($0.58)ViewN/AView Earnings Details
5/7/2015Q115($0.56)($0.43)ViewN/AView Earnings Details
3/23/2015Q4 2014($0.46)($0.47)ViewN/AView Earnings Details
11/13/2014Q314($0.54)($0.45)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.55)($0.38)ViewN/AView Earnings Details
5/8/2014Q1 2014($0.53)($0.86)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Flexion Therapeutics (NASDAQ:FLXN) Earnings Estimates

Current Year EPS Consensus Estimate: $-3.84 EPS
Next Year EPS Consensus Estimate: $-4.06 EPS

Dividends

Dividend History for Flexion Therapeutics (NASDAQ:FLXN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Flexion Therapeutics (NASDAQ FLXN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.98%
Institutional Ownership Percentage: 72.82%
Insider Trades by Quarter for Flexion Therapeutics (NASDAQ:FLXN)
Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics (NASDAQ FLXN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/21/2017Neil BodickInsiderBuy2,700$24.49$66,123.00View SEC Filing  
11/8/2017Michael D ClaymanInsiderBuy5,000$23.60$118,000.00View SEC Filing  
9/5/2017Yamo DenizInsiderBuy1,000$24.20$24,200.00View SEC Filing  
9/1/2017Yamo DenizInsiderBuy3,000$24.15$72,450.00View SEC Filing  
8/31/2017Yamo DenizInsiderBuy1,375$25.40$34,925.00View SEC Filing  
6/16/2017Mark StejbachDirectorBuy1,580$17.02$26,891.60View SEC Filing  
6/5/2017Michael D ClaymanInsiderBuy5,000$17.23$86,150.00View SEC Filing  
4/17/2017Neil BodickInsiderSell5,000$28.23$141,150.00View SEC Filing  
3/23/2017Frederick W DriscollCFOSell3,000$23.00$69,000.00View SEC Filing  
3/17/2017Neil BodickInsiderSell5,000$20.41$102,050.00View SEC Filing  
2/24/2017Neil BodickInsiderSell5,000$19.15$95,750.00View SEC Filing  
1/20/2017Neil BodickInsiderSell5,000$18.35$91,750.00View SEC Filing  
12/21/2016Neil BodickInsiderSell10,000$18.46$184,600.00View SEC Filing  
12/1/2016Samuel D ColellaDirectorBuy10,000$16.38$163,800.00View SEC Filing  
11/23/2016Michael D ClaymanInsiderBuy1,667$18.41$30,689.47View SEC Filing  
11/22/2016Michael D ClaymanInsiderBuy1,666$17.95$29,904.70View SEC Filing  
11/21/2016Michael D ClaymanInsiderBuy1,666$17.90$29,821.40View SEC Filing  
11/21/2016Samuel D ColellaDirectorBuy33,333$18.00$599,994.00View SEC Filing  
6/21/2016Samuel D ColellaDirectorBuy25,504$13.71$349,659.84View SEC Filing  
6/20/2016Samuel D ColellaDirectorBuy6,778$13.84$93,807.52View SEC Filing  
6/14/2016C Ann MerrifieldDirectorBuy1,000$13.39$13,390.00View SEC Filing  
6/8/2016Samuel D ColellaDirectorBuy714,285$14.00$9,999,990.00View SEC Filing  
5/20/2016Michael D ClaymanCEOBuy2,000$10.41$20,820.00View SEC Filing  
5/19/2016Michael D ClaymanCEOBuy2,000$9.65$19,300.00View SEC Filing  
5/19/2016Neil BodickInsiderBuy850$10.00$8,500.00View SEC Filing  
5/18/2016Michael D ClaymanCEOBuy2,000$10.23$20,460.00View SEC Filing  
5/18/2016Neil BodickInsiderBuy2,100$10.20$21,420.00View SEC Filing  
5/17/2016Frederick W DriscollCFOBuy2,500$9.87$24,675.00View SEC Filing  
5/17/2016Michael D ClaymanCEOBuy2,000$9.73$19,460.00View SEC Filing  
5/17/2016Neil BodickInsiderBuy800$9.60$7,680.00View SEC Filing  
5/16/2016Frederick W DriscollCFOBuy2,500$9.19$22,975.00View SEC Filing  
5/16/2016Michael D ClaymanCEOBuy2,000$9.51$19,020.00View SEC Filing  
5/16/2016Neil BodickInsiderBuy1,250$9.22$11,525.00View SEC Filing  
9/11/2015C Ann MerrifieldDirectorBuy1,000$23.00$23,000.00View SEC Filing  
6/22/2015A/S NovoMajor ShareholderSell150,000$20.61$3,091,500.00View SEC Filing  
3/16/2015Neil BodickInsiderSell4,000$25.28$101,120.00View SEC Filing  
3/10/2015Neil BodickInsiderSell4,000$24.26$97,040.00View SEC Filing  
3/4/2015Neil BodickInsiderSell4,000$23.45$93,800.00View SEC Filing  
2/26/2015Neil BodickInsiderSell4,000$22.44$89,760.00View SEC Filing  
12/17/2014A/S NovoMajor ShareholderBuy500,000$17.00$8,500,000.00View SEC Filing  
2/18/2014A/S NovoInsiderBuy692,308$13.00$9,000,004.00View SEC Filing  
2/18/2014Bradley J Phd BolzonDirectorBuy307,692$13.00$3,999,996.00View SEC Filing  
2/18/2014Sofinnova Partners SasMajor ShareholderBuy230,769$13.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Flexion Therapeutics (NASDAQ FLXN) News Headlines

Source:
DateHeadline
Flexion Therapeutics (FLXN) Buys Novel, Non-Opioid Asset for Osteoarthritis of the Knee - StreetInsider.comFlexion Therapeutics (FLXN) Buys Novel, Non-Opioid Asset for Osteoarthritis of the Knee - StreetInsider.com
www.streetinsider.com - December 14 at 5:54 PM
Flexion Therapeutics (FLXN) Buys Novel, Non-Opioid Asset for Osteoarthritis of the KneeFlexion Therapeutics (FLXN) Buys Novel, Non-Opioid Asset for Osteoarthritis of the Knee
www.streetinsider.com - December 13 at 5:31 PM
Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the KneeFlexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee
finance.yahoo.com - December 13 at 5:31 PM
Flexion Therapeutics (FLXN) Names Scott Kelley, MD as Chief Medical Officer - StreetInsider.comFlexion Therapeutics (FLXN) Names Scott Kelley, MD as Chief Medical Officer - StreetInsider.com
www.streetinsider.com - December 12 at 9:55 AM
Notable Monday Option Activity: KHC, RGLD, FLXNNotable Monday Option Activity: KHC, RGLD, FLXN
www.nasdaq.com - December 11 at 5:33 PM
Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical OfficerFlexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer
finance.yahoo.com - December 11 at 5:33 PM
Critical Comparison: Flexion Therapeutics (FLXN) vs. Its RivalsCritical Comparison: Flexion Therapeutics (FLXN) vs. Its Rivals
www.americanbankingnews.com - December 9 at 8:02 AM
Flexion Therapeutics (FLXN) Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA - StreetInsider.comFlexion Therapeutics (FLXN) Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA - StreetInsider.com
www.streetinsider.com - December 7 at 5:48 PM
Flexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension) in Bilateral Osteoarthritis of the KneeFlexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension) in Bilateral Osteoarthritis of the Knee
finance.yahoo.com - December 7 at 5:48 PM
Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare ConferenceFlexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 6 at 5:23 PM
Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)
globenewswire.com - December 5 at 10:10 AM
Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - December 4 at 5:20 PM
Flexion Therapeutics Inc (FLXN) Expected to Announce Quarterly Sales of $1.29 MillionFlexion Therapeutics Inc (FLXN) Expected to Announce Quarterly Sales of $1.29 Million
www.americanbankingnews.com - December 2 at 3:46 AM
Flexion's (FLXN) Zilretta Therapy to Fast Capture OA MarketFlexion's (FLXN) Zilretta Therapy to Fast Capture OA Market
finance.yahoo.com - December 1 at 4:50 PM
Stock Traders Purchase Large Volume of Flexion Therapeutics Call Options (FLXN)Stock Traders Purchase Large Volume of Flexion Therapeutics Call Options (FLXN)
www.americanbankingnews.com - November 30 at 3:40 AM
Flexion Therapeutics Target of Unusually Large Options Trading (FLXN)Flexion Therapeutics Target of Unusually Large Options Trading (FLXN)
www.americanbankingnews.com - November 30 at 3:40 AM
Flexion Therapeutics to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive ConferenceFlexion Therapeutics to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
finance.yahoo.com - November 28 at 5:21 PM
This Small-Cap Biotech Stock Is Onto Something BigThis Small-Cap Biotech Stock Is Onto Something Big
finance.yahoo.com - November 28 at 9:05 AM
Notable Monday Option Activity: FLXN, VER, AVGONotable Monday Option Activity: FLXN, VER, AVGO
www.nasdaq.com - November 27 at 5:47 PM
Todays Research Reports on Stocks to Watch: Flexion Therapeutics and Teva PharmaceuticalToday's Research Reports on Stocks to Watch: Flexion Therapeutics and Teva Pharmaceutical
finance.yahoo.com - November 27 at 5:47 PM
Health Care Sector Update for 11/24/2017: FLXN,CYTX,MDGS - NasdaqHealth Care Sector Update for 11/24/2017: FLXN,CYTX,MDGS - Nasdaq
www.nasdaq.com - November 24 at 4:26 PM
Flexion Therapeutics, Inc. (FLXN) Receives Consensus Rating of "Buy" from BrokeragesFlexion Therapeutics, Inc. (FLXN) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 23 at 9:36 PM
Flexion Therapeutics, Inc. (FLXN) Insider Neil Bodick Purchases 2,700 SharesFlexion Therapeutics, Inc. (FLXN) Insider Neil Bodick Purchases 2,700 Shares
www.americanbankingnews.com - November 22 at 8:45 PM
Flexion Therapeutics (FLXN) Reports Full Commercial Launch ... - StreetInsider.comFlexion Therapeutics (FLXN) Reports Full Commercial Launch ... - StreetInsider.com
www.streetinsider.com - November 21 at 12:27 AM
Flexion Therapeutics Announces Full Commercial Launch and Nationwide Availability of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension)Flexion Therapeutics Announces Full Commercial Launch and Nationwide Availability of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension)
finance.yahoo.com - November 20 at 7:27 PM
Flexion Therapeutics Named Top Place to Work for 2017 by The​ ​Boston​ ​Globe​ - GlobeNewswire (press release)Flexion Therapeutics Named Top Place to Work for 2017 by The​ ​Boston​ ​Globe​ - GlobeNewswire (press release)
globenewswire.com - November 19 at 4:05 AM
Flexion Therapeutics Named Top Place to Work for 2017 by The​ ​Boston​ ​Globe​Flexion Therapeutics Named Top Place to Work for 2017 by The​ ​Boston​ ​Globe​
finance.yahoo.com - November 18 at 8:50 AM
Head to Head Comparison: Flexion Therapeutics (FLXN) & Its CompetitorsHead to Head Comparison: Flexion Therapeutics (FLXN) & Its Competitors
www.americanbankingnews.com - November 17 at 1:42 PM
Flexion Therapeutics, Inc. (FLXN) Expected to Post Quarterly Sales of $1.29 MillionFlexion Therapeutics, Inc. (FLXN) Expected to Post Quarterly Sales of $1.29 Million
www.americanbankingnews.com - November 14 at 9:02 AM
-$1.09 Earnings Per Share Expected for Flexion Therapeutics, Inc. (FLXN) This Quarter-$1.09 Earnings Per Share Expected for Flexion Therapeutics, Inc. (FLXN) This Quarter
www.americanbankingnews.com - November 12 at 8:38 AM
Short Interest in Flexion Therapeutics, Inc. (FLXN) Increases By 19.5%Short Interest in Flexion Therapeutics, Inc. (FLXN) Increases By 19.5%
www.americanbankingnews.com - November 11 at 3:40 AM
Flexion Therapeutics, Inc. (FLXN) Rating Reiterated by Northland SecuritiesFlexion Therapeutics, Inc. (FLXN) Rating Reiterated by Northland Securities
www.americanbankingnews.com - November 10 at 11:20 PM
Flexion Therapeutics Stock Sees Short Interest Jump 19.6%Flexion Therapeutics Stock Sees Short Interest Jump 19.6%
www.thestreet.com - November 10 at 4:40 PM
Michael D. Clayman Acquires 5,000 Shares of Flexion Therapeutics, Inc. (FLXN) StockMichael D. Clayman Acquires 5,000 Shares of Flexion Therapeutics, Inc. (FLXN) Stock
www.americanbankingnews.com - November 9 at 12:34 PM
Edited Transcript of FLXN earnings conference call or presentation 6-Nov-17 9:30pm GMTEdited Transcript of FLXN earnings conference call or presentation 6-Nov-17 9:30pm GMT
finance.yahoo.com - November 8 at 7:00 AM
Is There Now An Opportunity In Flexion Therapeutics Inc (FLXN)?Is There Now An Opportunity In Flexion Therapeutics Inc (FLXN)?
finance.yahoo.com - November 8 at 7:00 AM
Flexion Therapeutics Reports Third-Quarter 2017 Financial Results ... - GlobeNewswire (press release)Flexion Therapeutics Reports Third-Quarter 2017 Financial Results ... - GlobeNewswire (press release)
globenewswire.com - November 7 at 3:49 AM
Flexion Therapeutics (FLXN) CEO Mike Clayman on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaFlexion Therapeutics' (FLXN) CEO Mike Clayman on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 7 at 3:49 AM
Flexion Therapeutics Getting Closer To Key Technical MeasureFlexion Therapeutics Getting Closer To Key Technical Measure
finance.yahoo.com - November 6 at 10:42 PM
Flexion Therapeutics Reports Third-Quarter 2017 Financial Results and Recent Business HighlightsFlexion Therapeutics Reports Third-Quarter 2017 Financial Results and Recent Business Highlights
finance.yahoo.com - November 6 at 10:42 PM
Flexion Therapeutics reports 3Q lossFlexion Therapeutics reports 3Q loss
finance.yahoo.com - November 6 at 10:42 PM
Flexion Therapeutics Highlights Two Clinical Data Presentations at the 2017 American College of Rheumatology Annual MeetingFlexion Therapeutics Highlights Two Clinical Data Presentations at the 2017 American College of Rheumatology Annual Meeting
finance.yahoo.com - November 2 at 7:59 PM
Zacks Investment Research Upgrades Flexion Therapeutics, Inc. (FLXN) to HoldZacks Investment Research Upgrades Flexion Therapeutics, Inc. (FLXN) to Hold
www.americanbankingnews.com - November 1 at 10:56 PM
Flexion - When Approvals Go Bad - Seeking AlphaFlexion - When Approvals Go Bad - Seeking Alpha
seekingalpha.com - October 31 at 5:39 AM
Flexion Therapeutics to Report Third-Quarter 2017 Financial Results on November 6, 2017Flexion Therapeutics to Report Third-Quarter 2017 Financial Results on November 6, 2017
finance.yahoo.com - October 30 at 7:34 PM
Flexion Therapeutics, Inc. (FLXN) Given a $39.00 Price Target at Wells Fargo & CompanyFlexion Therapeutics, Inc. (FLXN) Given a $39.00 Price Target at Wells Fargo & Company
www.americanbankingnews.com - October 30 at 9:22 AM
Flexion Therapeutics, Inc. (FLXN) Upgraded at Zacks Investment ResearchFlexion Therapeutics, Inc. (FLXN) Upgraded at Zacks Investment Research
www.americanbankingnews.com - October 26 at 9:26 PM
Relative Strength Alert For Flexion TherapeuticsRelative Strength Alert For Flexion Therapeutics
www.thestreet.com - October 26 at 7:05 PM
Flexion Therapeutics, Inc. (FLXN) Short Interest Up 25.2% in OctoberFlexion Therapeutics, Inc. (FLXN) Short Interest Up 25.2% in October
www.americanbankingnews.com - October 26 at 1:20 AM
Stocks on My Radar on This SellingStocks on My Radar on This Selling
finance.yahoo.com - October 25 at 10:33 PM

SEC Filings

Flexion Therapeutics (NASDAQ:FLXN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Flexion Therapeutics (NASDAQ:FLXN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Flexion Therapeutics (NASDAQ FLXN) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.